AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02808975
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injections administered as described in arm description
Trial: NCT00334867
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00334867
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01561482
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The simvastatin dose at treatment initiation will be 20 mg once daily (dose level -1), taken at bedtime for 2 weeks. After these 2 weeks, the subject will have blood work and, if no AST/ALT/CPK elevation grade greater than 1, will be escalated to 40 mg once daily (dose level 0), taken at bedtime. If AST or ALT or CPK elevation grade greater than 1 during the first 2 weeks, the subject will be evaluated every 2 weeks until resolution of toxicity to grade less than or equal to 1, and then the simvastatin dose will be increased to dose level 0.
Trial: NCT01458522
Drug: fPHT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If after initial treatment with fPHT any of the following occurs, the subject will have reached the end of the first treatment arm and will cross over and begin receiving the other drug, ie, the one not originally administered: the subject subsequently has another seizure within 24 hours following the 2-hour post-rebolus observation-only period; the subject does not receive a rebolus but has a seizure within 24 hours following the 2 hour post-bolus observation-only period; the subject experiences an AE that precludes further use of the first study drug.~If crossover occurs, the subject will start over with the second drug, going through the same observation-only period, rebolusing (if necessary), and study assessments with the second drug, beginning with the Baseline assessments.
Trial: NCT03111511
Drug: Drospirenone/Ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of drospirenone/ethinylestradiol 3 mg/0.02 mg (OC) tablets on Days 1 and 21.
Trial: NCT03251092
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00848796
Drug: Heparin Leo and Hepalean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage based on Heparin does response curve obtained from the Medtronic HMS plus
Trial: NCT01226732
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Taken orally twice daily on Days 1 through 14 of 21 day cycle.
Trial: NCT00419302
Drug: Technosphere/Insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00949377
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline
Trial: NCT01160120
Drug: generic FDC of TDF/3TC/EFV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who were on individual TDF 3TC and EFV regimen before baseline will undergo TDM at baseline. Therapeutic drug monitoring (TDM) of generic FDC of TDF/3TC/EFV will be done after 4 weeks, to ensure steady state. At baseline and week 4 safety data will be obtained. In order to assess the efficacy and the long term safety of this drug, at week 12, 24 and 48 viral load, CD4 and safety parameters will be obtained.
Trial: NCT03664037
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: each patient received 100 mL 0.9% NS IVI over 15 min (Placebo) 2 hours preoperatively
Trial: NCT01429519
Drug: RPh201, botanical drug product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical, three times per week for a period of 4 consecutive weeks, followed by a single follow up visit 3 months post end of the last treatment day
Trial: NCT03708237
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opaque gel capsules filled with methylcellulose 1500 filler
Trial: NCT02833805
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days -6 and -5: 14.5 mg/kg IV daily Days 3 and 4: 50 mg/kg IV daily
Trial: NCT03587766
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: fexinidazole
Trial: NCT01551303
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched nasal spray placebo
Trial: NCT01572324
Drug: Oxaliplatin, Fluorouracil, Leucovorin, Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAI of Oxaliplatin and Fluorouracil: Oxaliplatin 130mg/m2 in split daily doses for 3 days, Fluorouracil 3000 mg/m2 in split daily doses for 3 days. Intraarterial Oxaliplatin plus intravenous Leucovorin 200 mg/m2 simultaneously over 2 hours followed by intraarterial Fluorouracil over 22 hours on Days 1-3 of each cycle, repeat every 21 days. After 4-6 cycles of HAI, maintenance treatment continue, Maintenance of Oral capecitabine 1,000 mg/m2 twice a day from days 1-14, Cycles were repeated every 21 days.
Trial: NCT03436160
Drug: WR826647
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mcg Carbon-14 radio labeled WR826647 at an exposure no greater than 250 nCi per dose, administered both IV (bolus) and PO with a six half-life wash-out period between IV and PO administration. Interim analyses will be done at Day 14 following the IV dosing groups in order to assess half-lives of the three compounds to ensure the wash-out period between IV and PO dosing is at least six half-lives long.
Trial: NCT03436160
Drug: WR909388
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mcg Carbon-14 radio labeled WR909388 at an exposure no greater than 250 nCi per dose, administered both IV (bolus) and PO with a six half-life wash-out period between IV and PO administration. Interim analyses will be done at Day 14 following the IV dosing groups in order to assess half-lives of the three compounds to ensure the wash-out period between IV and PO dosing is at least six half-lives long.
Trial: NCT01798979
Drug: GLPG0634
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive multiple oral doses of GLPG0634 (200 mg daily for 7 days) from Days 2 to 8.
Trial: NCT03436160
Drug: WR909390
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mcg Carbon-14 radio labeled WR909309 at an exposure no greater than 250 nCi per dose, administered both IV (bolus) and PO with a six half-life wash-out period between IV and PO administration. Interim analyses will be done at Day 14 following the IV dosing groups in order to assess half-lives of the three compounds to ensure the wash-out period between IV and PO dosing is at least six half-lives long.
Trial: NCT01607385
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID, repeat doses
Trial: NCT01607385
Drug: GSK1614235
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID, co-dosed BID with last dosing day of active/placebo repeat doses
Trial: NCT02015988
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01651936
Drug: MK-8457 100 mg
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8457 100 mg dosed orally BID
Trial: NCT01651936
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX dosed at the stable dose received upon study entry
Trial: NCT01618396
Drug: Sedation drug (Propofol and Midazolam)
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Septic patients, after intubation, were initially sedated with propofol. During the second day of mechanical ventilation, propofol infusion was interrupted. When the patient awoke, the sedative drug was changed to midazolam. Sedation target was a Ramsay Scale score of 4 to 5.
Trial: NCT00676975
Drug: Traditional Chinese Medicine Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for 8 weeks
Trial: NCT03907267
Drug: Taurine Solution
RxNorm normalized name: Taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Taurine Solution
Trial: NCT00531622
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration, capsules
Trial: NCT03964402
Drug: intervention treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intervention treatment (any)
Trial: NCT02390063
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Metronomic cyclophosphamide (50mg bd)
Trial: NCT00119119
Drug: pentoxyphilline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01304043
Drug: chemotherapies protocols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatine 20 mg/m² IV Etoposide 100 mg/m² IV Bléomycine 30 mg IV
Trial: NCT03627611
Drug: Liothyronine
RxNorm normalized name: Liothyronine
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 months
Trial: NCT01405794
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile Water No Silver
Trial: NCT04962451
Drug: Placebo+ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo loading dose on day 1 (2 tablets, matched with ticagrelor 90mg), followed by placebo twice daily (matched with ticagrelor 90mg) Basic treatment: the first day received ASA loading dose, 300-325mg, and the server received ASA 75-100mg, once a day
Trial: NCT00976690
Drug: Azathioprine OR Mesalazine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine : 2mg/kg/day Mesalazine : 4g/day
Trial: NCT02593383
Drug: Adapalene + Clindamycin Hydrochloride
RxNorm normalized name: adapalene / benzoyl peroxide / clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% Adapalene + 1% Clindamycin Hydrochloride
Trial: NCT02593383
Drug: Adapalene + Clindamycin Hydrochloride
RxNorm normalized name: adapalene / benzoyl peroxide / clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% Adapalene + 2% Clindamycin Hydrochloride
Trial: NCT00703183
Drug: matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered as a single dose, orally
Trial: NCT01306123
Drug: Nascobal nasal spray (cyanocobalamin, USP)
RxNorm normalized name: vitamin B12 Nasal Spray [Nascobal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intranasal administration
Trial: NCT01306123
Drug: Vitamin B12-ratiopharm N, injection solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One single intramuscular administration
Trial: NCT01139788
Drug: LY2624587
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-900 mg, administered intravenously, weekly for a minimum of one (1) 28 day cycle.~If patients are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days).
Trial: NCT01921647
Drug: YH4808
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01921647
Drug: clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00497666
Drug: Rosiglitasone (retrospective observation)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02247414
Drug: Low Molecular Weight Heparin
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: From postoperative day 3, patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
Trial: NCT02024295
Drug: Ademethionine
RxNorm normalized name: Racemethionine
DrugBank: Racemethionine (DB13972)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ademethionine 1000mg ivgtt qd for 2 weeks, then orally 1000mg bid for 4 weeks.
Trial: NCT02024295
Drug: Polyene Phosphatidyl choline
RxNorm normalized name: lecithin
DrugBank: Lecithin (DB15834)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyene Phosphatidyl choline 10ml ivgtt qd for 2 weeks, then Polyene Phosphatidyl choline 456 mg tid orally for 4 weeks.
Trial: NCT02024295
Drug: Ademethionine
RxNorm normalized name: Racemethionine
DrugBank: Racemethionine (DB13972)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: after 6 weeks of core treatment stage, then ademethionine 1000mg bid or qd orally for 42 weeks
Trial: NCT00676845
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dosage form: tablet; frequency: daily; duration: 3 weeks
Trial: NCT04510298
Drug: SP-624
RxNorm normalized name: SPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Capsule
Trial: NCT04510298
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Capsule
Trial: NCT01783340
Drug: Azithromycin capsules
RxNorm normalized name: Azithromycin Capsules
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin capsules will be administered at each immunization
Trial: NCT01783340
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules will be administered at each immunization
Trial: NCT02153905
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
Trial: NCT00597051
Drug: ARD-0403
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06106074
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral
Trial: NCT02293837
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects assigned to this group will receive placebo intravenous (IV) infusions of either 8.0 mg/kg (body weight ≥ 30kg) or 10.0 mg/kg (body weight \<30kg) every 4 weeks for 24 weeks.
Trial: NCT05448586
Drug: Opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of balanced anesthesia including opioids during anesthesia for gynecologic cancer surgery
Trial: NCT01288209
Drug: TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100-mg capsule taken by mouth once daily for 12 or 24 weeks.
Trial: NCT02040090
Drug: Active rabies vaccine (US-FDA approved)
RxNorm normalized name: rabies virus vaccine flury-lep strain Injection [RabAvert]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28 On day 0, the day when the HRIG is given, the first vaccine dose could be given within few minutes from the time of HRIG injection was given and never be administered into the same anatomical site as the HRIG.
Trial: NCT03082833
Drug: AZD2014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD2014 is a selective dual mTOR kinase inhibitor targeting both mTORC1 (rapamycin sensitive) and mTORC2 (rapamycin insensitive) complexes of mammalian Target Of Rapamycin (mTOR).
Trial: NCT00583466
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline will be injected under the lesion to create submucosal cushion
Trial: NCT01732549
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules are identical to tasquinimod capsules in appearance and excipients but exclude the active compound (tasquinimod), to be taken orally once a day with water and food
Trial: NCT00351377
Drug: Enteric-coated Mycophenolate Sodium
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteric-coated Mycophenolate Sodium (EC-MPS) 180 mg and 360 mg tablets were administered orally in divided doses twice daily.
Trial: NCT00047723
Drug: minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03809039
Drug: MT-6345 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MT-6345 Placebo
Trial: NCT01494714
Drug: JNJ 10229570-AAA 1.2% cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
Trial: NCT01494714
Drug: Color-matched vehicle in a cream formulation containing 0 mg of JNJ 10229570-AAA
RxNorm normalized name: DIET FORMULATIONS FOR TREATMENT OF OBESITY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
Trial: NCT00513487
Drug: Dust mite extract, Fluticasone, Methacholine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dust mite extract, Fluticasone, Methacholine
Trial: NCT01675245
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an observational study. Velcade will be administered as per the recommended regimen. (Velcade, 1.3 mg/m2/dose, administered intravenously on days 1, 4, 8 and 11, for 2 weeks)
Trial: NCT02258464
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 6 cycles of saline injection
Trial: NCT02885662
Drug: CS-3150
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-3150 2.5 to 5.0 mg , orally.
Trial: NCT01755520
Drug: Placebo - Aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02388152
Drug: Lu AF20513, medium dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02388152
Drug: Lu AF20513, high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02388152
Drug: Lu AF20513, double high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01863641
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive placebo similar to intervention (shape, color and design) 1 oral unit daily.
Trial: NCT00376415
Drug: Lessertia Fructescens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received 400mg lessertia fructescens leaf powder capsules twice daily for 3 months.
Trial: NCT00376415
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received an identical placebo capsule twice daily for 3 months.
Trial: NCT02274090
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel consist of drug without the active component.
Trial: NCT02671188
Drug: GSK3050002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The 3 mL glass vial contains white to off-white lyophilized powder which requires reconstitution with sterile water for injection.Prepared as 100 milligrams per milliliter (mg/mL) solution; lower concentrations prepared by dilution with 0.9% weight by volume (w/v) sodium chloride Injection for infusion.
Trial: NCT02671188
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (0.9% sodium chloride) will be used as placebo.
Trial: NCT00389272
Drug: Ibuprofen, acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00220961
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets similar to pioglitazone tablets - 1 tablet/day
Trial: NCT02710994
Drug: CDFR0209
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release omeprazole 40 mg and sodium bicarbonate 1,100 mg
Trial: NCT00179738
Drug: CC5013
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05138484
Drug: experimental group 10% mouthwash of M. sylvestris extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To each patient was delivering a 150 ml bottle with the corresponding mouthwash. The indications for posology were: rinse with 10 ml of mouthwash for 1 minute in the mouth, every 12 hours for 7 days. To the follow-up of the intervention, was made telephone calls at least once a day to remember the rinse.
Trial: NCT00420784
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT00092053
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets
Trial: NCT00092053
Drug: ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg tablets
Trial: NCT04162002
Drug: Restylane® Lyft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filler Injection
Trial: NCT03836859
Drug: rhNGF 20μg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study Eye (For subjects randomized to rhNGF group) Day 1: One drop instilled into study eye (35 μL, corresponding to 0.70 μg of rhNGF).~Day 2, 3, 4, 5, 6: One drop six times a day (every 2h) into study eye (210 μL, corresponding to 4.20 μg of rhNGF).~Total dose in the study eye will be 31 drops (1085 μL, equivalent to 21.7 μg rhNGF) over 6 days.
Trial: NCT02737020
Drug: Rhodiola
RxNorm normalized name: RHODIOLA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhodiola rosea 200mg pill up to four times a day
Trial: NCT02737020
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: up to four times a day
Trial: NCT00556374
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5 mg zoledronic acid administered at a constant infusion rate
Trial: NCT03640247
Drug: Non-narcotic group regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-Narcotic Group. Receives only alternating acetaminophen and ibuprofen
Trial: NCT03640247
Drug: Narcotic group regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narcotic Group: Alternating acetaminophen and ibuprofen, with a prescription of 10 tablets oxycodone (or if needed based on patient allergies, hydrocodone 5 mg/tramadol 50 mg) for break through pain.